0001209191-21-044044.txt : 20210630 0001209191-21-044044.hdr.sgml : 20210630 20210630180659 ACCESSION NUMBER: 0001209191-21-044044 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210628 FILED AS OF DATE: 20210630 DATE AS OF CHANGE: 20210630 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mathers Edward T CENTRAL INDEX KEY: 0001328625 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40522 FILM NUMBER: 211063150 MAIL ADDRESS: STREET 1: C/O MEDIMMUNE, INC. STREET 2: ONE MEDIMMUNE WAY CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Monte Rosa Therapeutics, Inc. CENTRAL INDEX KEY: 0001826457 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 645 SUMMER STREET STREET 2: SUITE 102 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 617-949-2643 MAIL ADDRESS: STREET 1: 645 SUMMER STREET STREET 2: SUITE 102 CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-28 0 0001826457 Monte Rosa Therapeutics, Inc. GLUE 0001328625 Mathers Edward T 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 0 0 1 0 Common Stock 2021-06-28 4 C 0 2715968 A 2715968 I See Note 2 Common Stock 2021-06-28 4 C 0 3257328 A 5973296 I See Note 2 Common Stock 2021-06-28 4 C 0 669002 A 6642298 I See Note 2 Common Stock 2021-06-28 4 P 0 1050000 19.00 A 7692298 I See Note 2 Series A-2 convertible preferred stock 2021-06-28 4 C 0 9588725 D Common Stock 2715968 0 I See Note 2 Series B convertible preferred stock 2021-06-28 4 C 0 11500000 D Common Stock 3257328 0 I See Note 2 Series C convertible preferred Stock 2021-06-28 4 C 0 2361912 D Common Stock 669002 0 I See Note 2 Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest. /s/ Sasha Keough, attorney-in-fact 2021-06-30